Luke Walker, MD

Dr. Walker has served as a member of our board of directors since September 2024. Dr. Walker currently is the Chief Medical Officer of Umoja Biopharma, Inc., a clinical-stage biotech company. From October 2022 to August 2024, Dr. Walker was the Chief Medical Officer of Harpoon Therapeutics, which was acquired by Merck in March 2024. From March 2018 to October 2022, Dr. Walker was Vice President of Clinical Development at Seagen, which was acquired by Pfizer in 2023. Earlier, Dr. Walker was Senior Vice President of Clinical Development at Cascadian Therapeutics, which was acquired by Seagen in 2018. Dr. Walker began his career as a practicing medical oncologist and hematologist at Providence Regional Medical Center and with the Everett Clinic. Dr. Walker currently serves on the board of directors of Zentalis Pharmaceuticals, a public biopharmaceutical company.

Dr. Walker received his M.D. from the University of Oklahoma College of Medicine.